Review on reversed - phase chromatographic analysis of bexagliflozin: multifactorial effects on separation performance, and an Ich Q14 - aligned AQbD framework
Future Journal of Pharmaceuticals and Health Sciences · 24.04.2026 · 6 (2) · 75-90
DOI: 10.26452/fjphs.v6i2.565 ↗Kurz gefasst
Fachartikel in der Zeitschrift Future Journal of Pharmaceuticals and Health Sciences, online erschienen am 24.04.2026. Verfasst von {"name":"Yellamraju Padma Sree","email":"yellamrajupadmasri24@gmail.com","affili und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Bexagliflozin, a recently approved sodium – glucose cotransporter - 2 (SGLT - 2) inhibitor for type 2 diabetes mellitus, poses analytical challenges due to its low aqueous solubility, moderate lipophilicity, and susceptibility to degradation. These properties ne cessitate robust, stability - indicating chromatographic methods capable of accurate quantification in the presence of degradation products. This review provides a comprehensive, lifecycle - oriented evaluation of reported reversed - phase chromatographic method s, HPLC, UPLC, and LC – MS techniques, for Bexagliflozin analysis. Methods were systematically assessed based on chromatographic conditions, performance parameters, stability - indicating capability, and sustainability considerations. The analysis reveals that mobile - phase pH, organic solvent composition, and stationary - phase chemistry significantly influence retention, peak symmetry, and resolution, while efficiency is governed by particle size, flow rate, and temperature. Importantly, multifactor interactions play a critical role in determining method robustness and separation performance. However, inconsistent reporting of key chromatographic parameters limits inter - method comparison and robustness assessment. To address these limitations, an Analytical Quali ty by Design approach aligned with ICH Q14 is proposed, incorporating QTTP, ATP, CMAs, CPPs, and risk assessment tools. This work highlights the transition from empirical method development toward a mechanistic, multifactor - driven, and lifecycle - oriented a nalytical framework, enabling the design of robust, reproducible, and regulatory - compliant chromatographic methods for Bexagliflozin and related SGLT - 2 inhibitors.
Zitieren
APA
Sree","email":"yellamrajupadmasri24@gmail.com","affili, N. P., Eri","email":"yellamrajupadmasri24@gmail.com","affilia, N. K., Susmitha","email":"yellamrajupadmasri24@gmail.com","affiliat, N., Swathi","email":"yellamrajupadmasri24@gmail.com","af, N. V., & Swarnalatha","email":"yellamrajupadmasri24@gmail.com","affil, N. (2026). Review on reversed - phase chromatographic analysis of bexagliflozin: multifactorial effects on separation performance, and an Ich Q14 - aligned AQbD framework. Future Journal of Pharmaceuticals and Health Sciences, 6(2), 75-90. https://doi.org/10.26452/fjphs.v6i2.565
Vancouver
Sree","email":"yellamrajupadmasri24@gmail.com","affili NP, Eri","email":"yellamrajupadmasri24@gmail.com","affilia NK, Susmitha","email":"yellamrajupadmasri24@gmail.com","affiliat N, Swathi","email":"yellamrajupadmasri24@gmail.com","af NV, Swarnalatha","email":"yellamrajupadmasri24@gmail.com","affil N. Review on reversed - phase chromatographic analysis of bexagliflozin: multifactorial effects on separation performance, and an Ich Q14 - aligned AQbD framework. Future Journal of Pharmaceuticals and Health Sciences. 2026;6(2):75-90. doi:10.26452/fjphs.v6i2.565
BibTeX
@article{Sreeemailyellamrajupadmasrigmailcomaffili2026,
author = {Sree","email":"yellamrajupadmasri24@gmail.com","affili, "name":"Yellamraju Padma and Eri","email":"yellamrajupadmasri24@gmail.com","affilia, "name":"Gireesh Kumar and Susmitha","email":"yellamrajupadmasri24@gmail.com","affiliat, "name":"Aggarapu and Swathi","email":"yellamrajupadmasri24@gmail.com","af, "name":"Rallapalli Venkata and Swarnalatha","email":"yellamrajupadmasri24@gmail.com","affil, "name":"Dugasani},
title = {Review on reversed - phase chromatographic analysis of bexagliflozin: multifactorial effects on separation performance, and an Ich Q14 - aligned AQbD framework},
journal = {Future Journal of Pharmaceuticals and Health Sciences},
year = {2026},
volume = {6},
number = {2},
pages = {75--90},
doi = {10.26452/fjphs.v6i2.565}
}
EUVIMED